Inherited coagulopathy
Revision as of 11:42, 2 May 2023 by Warner-admin (talk | contribs) (Text replacement - "6 PubMed" to "6/ PubMed")
3 regimens on this page
3 variants on this page
|
Guidelines
ASH/ISTH/NHF/WFH
- 2021: James et al. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease
- 2021: Connell et al. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease
BSH
- 2020: Rayment et al. Guidelines on the use of prophylactic factor replacement for children and adults with Haemophilia A and B
"How I treat"
- 2020: Leebeek et al. How I manage pregnancy in carriers of hemophilia and patients with von Willebrand disease
- 2019: Young. How I treat children with haemophilia and inhibitors
- 2019: Lavin & O'Donnell How I treat low von Willebrand factor levels
Factor VIII deficiency (Hemophilia A), replacement products
To be completed
Factor VIII deficiency (Hemophilia A), without inhibitors, all lines of therapy
Emicizumab monotherapy
Regimen
| Study | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|
| Mahlangu et al. 2018 (HAVEN 3) | Phase 3 (E-esc) | No prophylaxis | Lower bleeding rate |
Supportive therapy
References
- HAVEN 3: Mahlangu J, Oldenburg J, Paz-Priel I, Negrier C, Niggli M, Mancuso ME, Schmitt C, Jiménez-Yuste V, Kempton C, Dhalluin C, Callaghan MU, Bujan W, Shima M, Adamkewicz JI, Asikanius E, Levy GG, Kruse-Jarres R. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med. 2018 Aug 30;379(9):811-822. link to original article PubMed
Factor VIII deficiency (Hemophilia A), with inhibitors, all lines of therapy
Emicizumab monotherapy
Regimen
| Study | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|
| Oldenburg et al. 2017 (HAVEN 1) | Phase 3 (E-esc) | No prophylaxis | Lower bleeding rate |
Supportive therapy
References
- HAVEN 1: Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young G, Santagostino E, Kruse-Jarres R, Negrier C, Kessler C, Valente N, Asikanius E, Levy GG, Windyga J, Shima M. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017 Aug 31;377(9):809-818. Epub 2017 Jul 10. link to original article PubMed
- HAVEN 2: Young G, Liesner R, Chang T, Sidonio R, Oldenburg J, Jiménez-Yuste V, Mahlangu J, Kruse-Jarres R, Wang M, Uguen M, Doral MY, Wright LY, Schmitt C, Levy GG, Shima M, Mancuso ME. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood. 2019 Dec 12;134(24):2127-2138. link to original article PubMed
Rituximab monotherapy
Regimen
| Study | Evidence |
|---|---|
| Leissinger et al. 2014 | Phase 2 |
Immunosuppressive therapy
- Rituximab (Rituxan) 375 mg/m2 IV once per day on days 1, 8, 15, 22
28-day course
References
- Kempton CL, Allen G, Hord J, Kruse-Jarres R, Pruthi RK, Walsh C, Young G, Soucie JM. Eradication of factor VIII inhibitors in patients with mild and moderate hemophilia A. Am J Hematol. 2012 Sep;87(9):933-6. link to PMC article does not contain dosing details PubMed
- Leissinger C, Josephson CD, Granger S, Konkle BA, Kruse-Jarres R, Ragni MV, Journeycake JM, Valentino L, Key NS, Gill JC, McCrae KR, Neufeld EJ, Manno C, Raffini L, Saxena K, Torres M, Marder V, Bennett CM, Assmann SF. Rituximab for treatment of inhibitors in haemophilia A: a phase II study. Thromb Haemost. 2014 Sep 2;112(3):445-58. link to original article link to PMC article PubMed
Factor IX deficiency (Hemophilia B), all lines of therapy
To be completed